LAB vs LHX · rev $41.3M vs P/E 34, rev $5.88B
Standard Biotools Inc (LAB) versus L3Harris Technologies Inc (LHX) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
L3Harris Technologies Inc (LHX) is a aerospace & defense company listed on US.
Latest reported LAB revenue for 2026-06-30 was $41.3M. Net income was $100.3M. Revenue was up 95.1% from 2026-03-31 to 2026-06-30. LAB currently screens at market cap $317.1M.
Latest reported LHX revenue for 2026-07-03 was $5.88B. Net income was $600.0M. Revenue was up 2.4% from 2026-04-03 to 2026-07-03. LHX currently screens at market cap $58.72B and trailing P/E 34.3.
LAB currently screens at market cap $317.1M. LHX currently screens at market cap $58.72B and trailing P/E 34.3.
Not investment advice. Open the LAB and LHX stock pages for the full models.
Not investment advice.